Condition: Macular Telangiectasia Type 2 (MacTel) · Sponsor: Neurotech Pharmaceuticals
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.
This description comes directly from the study's public registry record.
Patricia Davis · 401-333-3880 · p.davis@neurotechusa.com
Always discuss trial participation with your own doctor first.
| Scripps Health | La Jolla, California, United States | Not Yet Recruiting |
| Jules Stein Eye Institute/UCLA | Los Angeles, California, United States | Not Yet Recruiting |
| Stanford University School of Medicine | Palo Alto, California, United States | Not Yet Recruiting |
| Bay Area Retina Associates | Walnut Creek, California, United States | Recruiting |
| Colorado Retina | Lakewood, Colorado, United States | Not Yet Recruiting |
| Bascom Palmer | Miami, Florida, United States | Not Yet Recruiting |
| Emory Eye Center | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| National Eye Institute | Bethesda, Maryland, United States | Not Yet Recruiting |
| Cumberland Valley Retina Consultants | Frederick, Maryland, United States | Not Yet Recruiting |
| Massachusetts Eye and Ear Infirmary, Retina Service | Boston, Massachusetts, United States | Not Yet Recruiting |
| Foundation for Vision Research | Grand Rapids, Michigan, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06971939